SARS-CoV-2 Subunit Virus-like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study

Public health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of “Betuvax-CoV-2”, a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Vakhrusheva, Anna V., Kudriavtsev, Aleksandr V., Kryuchkov, Nickolay A., Deev, Roman V., Frolova, Maria E., Blagodatskikh, Konstantin A., Djonovic, Milana, Nedorubov, Andrey A., Odintsova, Elena, Ivanov, Aleksandr V., Romanovskaya-Romanko, Ekaterina A., Stukova, Marina A., Isaev, Artur A., Krasilnikov, Igor V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412395/
https://www.ncbi.nlm.nih.gov/pubmed/36016181
http://dx.doi.org/10.3390/vaccines10081290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412395/
https://www.ncbi.nlm.nih.gov/pubmed/36016181
http://dx.doi.org/10.3390/vaccines10081290

Ejemplares similares